{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-118882","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.387371+00:00","generated_at":"2026-05-21T16:31:31.894962+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spero Q1 loss $13.9M, revenue $5.9M; appoints new CEO, tebipenem trial interim on track","bullets":["Net loss $13.9M ($0.25/share) vs $12.7M loss in Q1 2024; revenue $5.9M down from $9.3M.","Cash $48.9M plus $23.75M earned GSK milestone payments provides runway into Q2 2026.","Esther Rajavelu appointed President & CEO effective May 2, 2025; continues as CFO & Treasurer.","Phase 3 PIVOT-PO interim analysis for tebipenem HBr expected Q2 2025; SPR720 program suspended after missing endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-118882","json":"https://secwatch.observer/filing/0001193125-25-118882.json","markdown":"https://secwatch.observer/filing/0001193125-25-118882.md","text":"https://secwatch.observer/filing/0001193125-25-118882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312525118882/0001193125-25-118882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312525118882/d918635d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:31:31.894962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}